GGrantIndex
← Leaderboards

Ingunn Margarete Stromnes

University Of Minnesota

$4,130,375
Attributed
$4,130,375
Total exposure
2
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $877.8K · FY202125
$1M$750K$500K$250K$0
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,130,375 · 2

By mechanism

R01$4,130,375 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of Minnesota

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Neoplasm Metastasis

Research focus

Neoplasm MetastasisPancreatic Cancer PatientsMediatingMyeloid CellsMalignant Neoplasm Of PancreasNeoplastic CellImmunotherapyMalignant NeoplasmsEngineered T CellsMortalityAffinityAnimal ModelAnimalsIn VivoEffective TherapyImmuneDiagnosisCancer EtiologyAntigen-Specific T CellsCellsCell PhysiologyMesothelinAntitumor EffectPancreatic Ductal Adenocarcinoma

Grant awards (13)

Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma$431,993
R01 · FY2025 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$354,563
R01 · FY2025 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$91,282
R01 · FY2025 · CA · contact PI
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma$410,395
R01 · FY2024 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$336,835
R01 · FY2024 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$86,718
R01 · FY2024 · CA · contact PI
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma$423,354
R01 · FY2023 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$347,471
R01 · FY2023 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$91,282
R01 · FY2023 · CA · contact PI
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma$423,354
R01 · FY2022 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$347,471
R01 · FY2022 · CA · contact PI
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma$431,094
R01 · FY2021 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$354,563
R01 · FY2021 · CA · contact PI